Published online Apr 15, 2023. doi: 10.4251/wjgo.v15.i4.617
Peer-review started: December 4, 2022
First decision: December 26, 2022
Revised: January 9, 2023
Accepted: March 8, 2023
Article in press: March 8, 2023
Published online: April 15, 2023
Processing time: 128 Days and 17.6 Hours
Hepatocellular carcinoma (HCC) is a common malignant tumor that affecting many people's lives globally. The common risk factors for HCC include being overweight and obese. The liver is the center of lipid metabolism, synthesizing most cholesterol and fatty acids. Abnormal lipid metabolism is a significant feature of metabolic reprogramming in HCC and affects the prognosis of HCC patients by regulating inflammatory responses and changing the immune microenvironment. Targeted therapy and immunotherapy are being explored as the primary treatment strategies for HCC patients with unresectable tumors. Here, we detail the specific changes of lipid metabolism in HCC and its impact on both these therapies for HCC. HCC treatment strategies aimed at targeting lipid metabolism and how to integrate them with targeted therapy or immunotherapy rationally are also presented.
Core Tip: This review systematically summarizes the aberrant changes of lipid metabolism in hepatocellular carcinoma (HCC), and for the first time expounds the impact of lipid metabolism on HCC targeted therapy and immunotherapy. It vividly displayed the changes of lipid metabolism in HCC and the targets of some reagents by drawing figures, and summarized the impact of lipid metabolism related reagents on HCC targeted therapy and immunotherapy through table.
